Basic Information
Silodyx
Regulatory Information
EMEA/H/C/001209
Authorised
January 29, 2010
17
March 14, 2025
Company Information
Ireland
Raheens East Ringaskiddy Co. Cork
Recordati Ireland Ltd.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).